{"id":8519,"date":"2022-01-07T08:00:00","date_gmt":"2022-01-07T08:00:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=8519"},"modified":"2024-05-02T09:29:01","modified_gmt":"2024-05-02T07:29:01","slug":"granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/","title":{"rendered":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Koroku+M&amp;cauthor_id=33902268\">Miki Koroku<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Omori+T&amp;cauthor_id=33902268\">Teppei Omori<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kambayashi+H&amp;cauthor_id=33902268\">Harutaka Kambayashi<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Murasugi+S&amp;cauthor_id=33902268\">Shun Murasugi<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kuriyama+T&amp;cauthor_id=33902268\">Tomoko Kuriyama<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ikarashi+Y&amp;cauthor_id=33902268\">Yuichi Ikarashi<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yonezawa+M&amp;cauthor_id=33902268\">Maria Yonezawa<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Arimura+K&amp;cauthor_id=33902268\">Ken Arimura<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Karasawa+K&amp;cauthor_id=33902268\">Kazunori Karasawa<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-3\">3<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hanafusa+N&amp;cauthor_id=33902268\">Norio Hanafusa<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-4\">4<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kawana+M&amp;cauthor_id=33902268\">Masatoshi Kawana<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/#affiliation-5\">5<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Tokushige+K&amp;cauthor_id=33902268\">Katsutoshi Tokushige<\/a><sup>\u00a0<\/sup><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Intest Res <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=%22Intest+Res%22%5Bjour%5D&amp;sort=date&amp;sort_order=desc\"><\/a>2022 Jan;20(1):150-155.\u00a0doi: 10.5217\/ir.2020.00148.\u00a0Epub 2021 Mar 12<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8831771\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8831771\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Miki Koroku\u00a01,\u00a0Teppei Omori\u00a01,\u00a0Harutaka Kambayashi\u00a01,\u00a0Shun Murasugi\u00a01,\u00a0Tomoko Kuriyama\u00a01,\u00a0Yuichi Ikarashi\u00a01,\u00a0Maria Yonezawa\u00a01,\u00a0Ken Arimura\u00a02,\u00a0Kazunori Karasawa\u00a03,\u00a0Norio Hanafusa\u00a04,\u00a0Masatoshi Kawana\u00a05,\u00a0Katsutoshi Tokushige\u00a0 Intest Res 2022 Jan;20(1):150-155.\u00a0doi: 10.5217\/ir.2020.00148.\u00a0Epub 2021 Mar 12 Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[631,147,325,157,424,464,306],"class_list":["post-8519","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-case","scientific_tags-clinical-remission","scientific_tags-covid-19","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-treament","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/<\/a>\r\n\r\n<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8831771\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8831771\/<\/a>"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Miki Koroku\u00a01,\u00a0Teppei Omori\u00a01,\u00a0Harutaka Kambayashi\u00a01,\u00a0Shun Murasugi\u00a01,\u00a0Tomoko Kuriyama\u00a01,\u00a0Yuichi Ikarashi\u00a01,\u00a0Maria Yonezawa\u00a01,\u00a0Ken Arimura\u00a02,\u00a0Kazunori Karasawa\u00a03,\u00a0Norio Hanafusa\u00a04,\u00a0Masatoshi Kawana\u00a05,\u00a0Katsutoshi Tokushige\u00a0 Intest Res 2022 Jan;20(1):150-155.\u00a0doi: 10.5217\/ir.2020.00148.\u00a0Epub 2021 Mar 12 Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T07:29:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/\",\"name\":\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2022-01-07T08:00:00+00:00\",\"dateModified\":\"2024-05-02T07:29:01+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/","og_locale":"fr_FR","og_type":"article","og_title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte","og_description":"Miki Koroku\u00a01,\u00a0Teppei Omori\u00a01,\u00a0Harutaka Kambayashi\u00a01,\u00a0Shun Murasugi\u00a01,\u00a0Tomoko Kuriyama\u00a01,\u00a0Yuichi Ikarashi\u00a01,\u00a0Maria Yonezawa\u00a01,\u00a0Ken Arimura\u00a02,\u00a0Kazunori Karasawa\u00a03,\u00a0Norio Hanafusa\u00a04,\u00a0Masatoshi Kawana\u00a05,\u00a0Katsutoshi Tokushige\u00a0 Intest Res 2022 Jan;20(1):150-155.\u00a0doi: 10.5217\/ir.2020.00148.\u00a0Epub 2021 Mar 12 Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T07:29:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/","name":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2022-01-07T08:00:00+00:00","dateModified":"2024-05-02T07:29:01+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19-a-case-report\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/8519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=8519"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=8519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}